Status: Recruiting
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.
Participants needed: 50
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Telix Pharmaceuticals (Innovations) Pty LimitedUpdated: Apr 16, 2026Locations: 4
Eligibility criteria
Previously confirmed neuropathological diagnosis of glioblastoma, IDH-wildtype a... [+12]
Prior course with external beam radiation to the brain in the past 3 months. Pri... [+14]